Parameters predicting survival outcome in glioblastoma


Session type:

Gurdip Azad, Elena Wilson, Katharine Pigott, Robert Bradford

Royal Free Hospital, London, UK


Glioblastoma is the commonest primary brain tumour in adults with reported median survival of less than a year. Concurrent radiotherapy (RT) and temozolomide (TMZ) has produced clinical benefits and a statistically significant improvement in survival. We present a review of our experience at the Royal Free Hospital.

Retrospective review of patients with glioblastoma over a period of 54 months assessing whether age of the patient, site of the tumour or surgery prior to commencing RT/TMZ affected median survival (MS). The importance and incidence of pseudo-progression was also reviewed.

Patients who received RT/TMZ over a 54 month period were identified from electronic patient records and via multidisciplinary meetings. Data including age, site of tumour, surgery (debulking or biopsy), response (radiological and clinical) and median survival was obtained from case notes.

Total number of patients identified was 75 with a median follow-up of 24 months. Patients under 50 years of age had a MS of 14 months compared to 10 months in those over 50.